Intensity Therapeutics, Inc. (INTS) Misses Q2 EPS by 4c

Intensity Therapeutics, Inc. (NASDAQ: INTS) reported Q2 EPS of ($0.36), $0.04 worse than the analyst estimate of ($0.32).

For earnings history and earnings-related data on Intensity Therapeutics, Inc. (INTS) click here.

You May Also Be Interested In

• General Mills (GIS) Tops Q1 EPS by 3c
• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• Baird Reiterates Outperform Rating on On Holding AG (ONON)